Revolution Medicines, Inc. (RVMD)

Accolade Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-812.06	-600.09	-436.37	-248.71	-187.09	-108.16
Depreciation & Amortization	12.68	10.72	8.21	8.56	6.23	5.45
Other Amortization	1.1	1.1	1.1	1.1	1.1	1.1
Loss (Gain) From Sale of Assets	0	0.12	0.05	0.02	0.12	-
Loss (Gain) From Sale of Investments	-35.98	-44.57	-22.21	-3.08	3.01	0.97
Stock-Based Compensation	97.13	79.2	61.77	31.2	20.72	8.89
Other Operating Activities	4.49	-4.32	0.12	-	-	-
Change in Accounts Receivable	-	1.25	3.42	1.26	0.46	2.34
Change in Accounts Payable	27.07	-6.47	32.47	7.29	2.24	0.31
Change in Unearned Revenue	-	-	-4.46	-14.47	-1.66	-11.26
Change in Other Net Operating Assets	24.19	6.38	9.23	-7.14	7.68	0.68
Operating Cash Flow	-684.9	-557.44	-350.57	-224.4	-147.18	-100.06
Capital Expenditures	-15.46	-10.31	-7.73	-10.82	-6.53	-2.93
Investment in Securities	-380.59	-544.09	-334.87	-13.3	-135.59	-231.3
Investing Cash Flow	-396.05	-554.39	-342.6	-24.12	-142.12	-234.23
Issuance of Common Stock	862.87	863.71	392.39	301.39	294.6	422.78
Repurchase of Common Stock	-	-	-4.03	-	-	-
Other Financing Activities	345.69	95.71	840.83	0.04	-0.42	-
Financing Cash Flow	1,209	959.41	1,229	301.43	294.18	422.78
Net Cash Flow	127.61	-152.42	536.03	52.92	4.88	88.48
Free Cash Flow	-700.36	-567.74	-358.3	-235.22	-153.71	-103
Free Cash Flow Margin	-	-	-3094.14%	-664.83%	-522.99%	-239.62%
Free Cash Flow Per Share	-3.90	-3.38	-3.17	-2.92	-2.11	-1.88
Levered Free Cash Flow	-396.29	-347.69	-155.2	-132.84	-84.69	-58.24
Unlevered Free Cash Flow	-396.29	-347.69	-155.01	-132.84	-84.68	-58.19
Change in Working Capital	50.49	0.41	36.75	-13.49	8.72	-8.3

Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q